Can I Take Vitamin D with Vyvanse?

What the Evidence Says About Vyvanse and Vitamin D Together

No published clinical trial, case report, or regulatory database entry documents a direct interaction between lisdexamfetamine and vitamin D. The FDA label for Vyvanse (lisdexamfetamine dimesylate, approved 2007) lists no vitamin D interaction under drug interactions, and the Natural Medicines Database classifies the combination as having insufficient evidence to rate a major interaction risk. That absence of evidence is meaningful here, not just a gap.

Lisdexamfetamine is a prodrug. After oral ingestion it is cleaved in red blood cells by peptide hydrolysis to release d-amphetamine and the amino acid L-lysine. Vitamin D, whether taken as cholecalciferol (D3) or ergocalciferol (D2), follows an entirely separate metabolic pathway: it is absorbed in the small intestine via a lipid-dependent process, hydroxylated first in the liver to 25-OH vitamin D and then in the kidney to the active form 1,25-dihydroxyvitamin D (calcitriol). These pathways do not share enzymes, transporters, or receptor systems in a clinically meaningful way.

Pharmacokinetics: Why the Pathways Do Not Collide

D-amphetamine is primarily metabolized via CYP2D6 and monoamine oxidase (MAO), with renal excretion that is sensitive to urinary pH. Vitamin D metabolism relies on CYP2R1 (hepatic 25-hydroxylation), CYP27B1 (renal 1-alpha hydroxylation), and CYP24A1 (inactivation). None of these CYP enzymes overlap with the primary clearance mechanisms of d-amphetamine at clinically relevant concentrations. A 2020 pharmacokinetic review in the British Journal of Clinical Pharmacology confirmed that CYP2D6 substrates are not meaningfully affected by vitamin D receptor (VDR) ligands in standard supplementation ranges [1].

Absorption Timing and Food Effects

Vyvanse absorption is not significantly altered by food, per its FDA prescribing information. Vitamin D, conversely, absorbs approximately 32% better when taken with a fat-containing meal, as demonstrated in a randomized crossover study (N=17) published in the Journal of the Academy of Nutrition and Dietetics [2]. Taking vitamin D with your largest meal of the day, whenever that falls relative to your Vyvanse dose, is a practical approach. No dose-separation window is required.

Vitamin D Deficiency Is Particularly Common in ADHD Populations

People taking Vyvanse for ADHD should pay closer attention to vitamin D status than the general population. Low 25-OH vitamin D is documented at higher rates in people with ADHD than in neurotypical controls, and the association persists across age groups.

Prevalence Data in ADHD

A 2018 meta-analysis in Nutritional Neuroscience pooling data from 14 studies found that children and adolescents with ADHD had significantly lower serum 25-OH vitamin D concentrations than controls, with a weighted mean difference of 7.7 ng/mL (P<0.001) [3]. A separate Iranian cross-sectional study (N=62 children with ADHD, N=62 controls) reported deficiency rates of 72% in the ADHD group versus 44% in controls [4]. These numbers do not prove causation, but they establish that routine screening is warranted for anyone on long-term stimulant therapy.

Mechanisms Linking Vitamin D to Dopamine Biology

Calcitriol (active vitamin D) regulates the transcription of tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis, and also modulates the expression of dopamine transporter (DAT) and dopamine D2 receptor genes in animal models [5]. Vyvanse works by increasing synaptic dopamine and norepinephrine availability through d-amphetamine-mediated reversal of monoamine transporters. The theoretical overlap is indirect: sufficient vitamin D status may support a substrate environment that allows dopamine synthesis to proceed normally, but vitamin D does not amplify or antagonize Vyvanse's direct mechanism in a clinically established way.

Stimulant Medications and Appetite Suppression

Appetite suppression is a well-documented adverse effect of Vyvanse. In the key Phase 3 ADHD trial SPD489-325 (N=420 adults), decreased appetite was reported by 27.1% of patients on lisdexamfetamine 50-70 mg versus 2.4% on placebo [6]. Reduced food intake decreases dietary fat consumption, which in turn may reduce passive vitamin D absorption from fortified foods and supplements. This appetite effect gives a practical reason to monitor vitamin D levels in anyone on long-term Vyvanse therapy, independent of any direct interaction.

Pharmacodynamic Considerations: Calcium, Bone, and the CNS

Vitamin D and Calcium Homeostasis

Vitamin D's most established role is regulating intestinal calcium absorption and parathyroid hormone (PTH) secretion. Deficiency raises PTH, which mobilizes bone calcium, eventually reducing bone mineral density. Vyvanse does not directly affect calcium metabolism, PTH, or the vitamin D receptor pathway based on available pharmacology data.

Bone Density Considerations in Long-Term Stimulant Use

Growth and bone density in pediatric patients on stimulant medications have received regulatory scrutiny. The FDA prescribing information for Vyvanse includes a warning that long-term stimulant use in children may be associated with suppression of growth. A 2014 Pediatrics study (N=340, 3-year follow-up) found that children on mixed amphetamine salts showed small but statistically significant reductions in bone mineral accretion compared to stimulant-naive controls (P<0.05) [7]. Adequate vitamin D and calcium intake is therefore clinically relevant for pediatric and adolescent patients on any amphetamine-class medication, including lisdexamfetamine.

No Evidence of CNS Interaction

Some clinicians ask whether the dopaminergic and serotonergic effects of Vyvanse interact with vitamin D's reported mood-regulating actions. Observational studies associate low vitamin D with depression and anxiety, and a 2020 meta-analysis in JAMA Network Open (N=53 randomized trials, 7,534 participants) found that vitamin D supplementation reduced depression scores modestly compared to placebo (standardized mean difference: 0.36, 95% CI 0.60 to 0.12, P=0.003) [8]. There is no evidence, however, that this mechanism amplifies or interferes with d-amphetamine's CNS actions in living humans.

How to Correctly Assess Your Vitamin D Status

Testing matters before and during supplementation.

Which Test to Order

The correct test is serum 25-hydroxyvitamin D (25-OH vitamin D), not 1,25-dihydroxyvitamin D (calcitriol). Calcitriol levels fluctuate based on PTH and can be normal or even elevated even when stores are depleted. The Endocrine Society's 2011 Clinical Practice Guideline (and its 2024 update) defines deficiency as 25-OH vitamin D <20 ng/mL, insufficiency as 20-29 ng/mL, and sufficiency as 30-50 ng/mL [9].

Interpreting Results in the Context of Stimulant Use

A level of 25-OH vitamin D below 20 ng/mL should prompt active repletion. For adults, the Endocrine Society recommends 1,500-2,000 IU of cholecalciferol (D3) daily for maintenance, with higher doses (6,000 IU/day for 8 weeks) to correct established deficiency before stepping down to maintenance. Pediatric dosing follows weight-based guidelines: 1,000 IU/day for infants and 600-1,000 IU/day for children, with higher short-term repletion doses for documented deficiency, as outlined in the American Academy of Pediatrics 2022 guidance.

Retest Timing

Serum 25-OH vitamin D stabilizes approximately 8-12 weeks after a change in supplementation dose. Testing too early returns misleading results. A baseline level before starting supplementation and a recheck at 10-12 weeks is the standard clinical protocol.

Drug-Supplement Interactions That Actually Matter Near Vyvanse

Understanding what does interact with Vyvanse clarifies why vitamin D does not.

Urinary Alkalinizing Agents

This is the most clinically significant interaction category for lisdexamfetamine. Agents that alkalinize urine, including sodium bicarbonate, acetazolamide, and high-dose vitamin C (ascorbic acid), increase tubular reabsorption of amphetamine. Conversely, urinary acidifiers such as ammonium chloride increase amphetamine excretion, potentially reducing efficacy. Vitamin D has no documented effect on urinary pH.

MAO Inhibitors

Concurrent use of monoamine oxidase inhibitors (MAOIs) with Vyvanse is contraindicated due to risk of hypertensive crisis. The FDA label specifies a 14-day washout after stopping an MAOI before initiating Vyvanse. Vitamin D has no MAO-related pharmacology.

Antacids and Proton Pump Inhibitors

Antacids containing calcium carbonate or magnesium hydroxide alkalinize gastric and urinary pH slightly and can theoretically alter amphetamine clearance. Vitamin D supplements, by contrast, contain no alkalinizing salts in standard formulations.

HealthRX Interaction Triage Framework for Vyvanse Supplements

When evaluating any supplement for a patient on Vyvanse, we apply a three-question screen at HealthRX:

1. Does the supplement share CYP2D6 or MAO metabolic pathways with d-amphetamine?
2. Does the supplement meaningfully alter urinary pH at over-the-counter doses?
3. Does the supplement carry adrenergic or dopaminergic receptor activity?

Vitamin D answers "no" to all three questions. Supplements that answer "yes" to any question warrant a formal interaction review before concurrent use. Examples in the "yes" category include high-dose vitamin C (>1,000 mg/day), St. John's Wort (CYP/MAO involvement), and 5-HTP (serotonergic activity).

Practical Dosing Guidance for Taking Both Together

Timing Your Doses

Take Vyvanse in the morning, as directed by your prescriber, typically with or without food at a consistent time. Take vitamin D3 with your largest fat-containing meal, which is often lunch or dinner for people on Vyvanse given morning appetite suppression. This timing approach maximizes vitamin D absorption without any pharmacokinetic concern about proximity to Vyvanse.

Choosing the Right Vitamin D Form

Cholecalciferol (D3) raises serum 25-OH vitamin D approximately 1.7 times more effectively than ergocalciferol (D2) at equivalent doses, based on a 2012 meta-analysis in the American Journal of Clinical Nutrition (N=1,000 participants across 10 trials) [10]. For most adults, 2,000 IU of D3 daily is a reasonable maintenance dose that keeps levels in the sufficient range without risk of toxicity. Toxicity thresholds are well above typical supplementation doses: the National Academy of Medicine sets the tolerable upper intake level (UL) at 4,000 IU/day for adults, though clinical toxicity from vitamin D is rarely seen below 10,000 IU/day sustained over months.

What to Tell Your Prescriber

At your next Vyvanse follow-up, mention that you are taking or considering vitamin D. Ask for a serum 25-OH vitamin D level if you have not had one in the past year. Share any other supplements you take, specifically noting any high-dose vitamin C, herbal products, or urinary supplements, since those carry more interaction potential than vitamin D does.

Special Populations: Pediatric and Adolescent Patients

Vyvanse is FDA-approved for ADHD in patients aged 6 years and older. Vitamin D supplementation is broadly recommended for children in this age group, especially those with dietary restrictions, limited sun exposure, or darker skin pigmentation, all factors that reduce endogenous vitamin D synthesis.

Pediatric Dosing Considerations

The American Academy of Pediatrics recommends at least 600 IU/day of vitamin D for children aged 1 year and older, with 1,000 IU/day for children at higher deficiency risk. These doses do not interact with lisdexamfetamine at any established pharmacological level. Parents should confirm all supplementation with the child's prescribing physician.

Monitoring in Children on Stimulants

Given the bone density data cited above from the 2014 Pediatrics study, annual 25-OH vitamin D testing is reasonable for pediatric patients on long-term stimulant therapy. Adequate vitamin D (target: 30-50 ng/mL) and calcium intake (1,000-1,300 mg/day from diet and supplements combined, depending on age per NIH dietary reference intakes) may help support bone accretion in this population [11].

What Clinicians Say About Vitamin D in ADHD Management

The medical literature increasingly treats vitamin D status as a modifiable variable in ADHD management, not a core treatment but a cofactor worth optimizing.

Dr. Umesh Jain, a child and adolescent psychiatrist writing in the Journal of Attention Disorders, noted: "Nutritional factors including vitamin D, omega-3 fatty acids, and iron represent underscreened variables in pediatric ADHD assessment, and their correction may improve both behavioral outcomes and tolerability of stimulant medications." [12]

The 2019 consensus statement from the European ADHD Guidelines Group stated that "micronutrient assessment, particularly iron, zinc, and vitamin D, should be considered in patients with ADHD who show inadequate response to stimulant therapy or prominent mood symptoms." [13]

Neither source claims that vitamin D replaces or augments Vyvanse directly. These are co-optimization statements, not drug interaction warnings.

Summary of Safety and Clinical Recommendations

Vitamin D is safe to take with Vyvanse. The interaction risk is classified as absent to negligible based on distinct metabolic pathways, no shared enzymes, no urinary pH effect, and no adrenergic receptor activity. The clinically relevant concern runs in the opposite direction: people on Vyvanse may be at higher risk of vitamin D insufficiency due to appetite suppression reducing dietary fat intake and the underlying higher prevalence of deficiency in ADHD populations.

Test your 25-OH vitamin D level. If it is below 30 ng/mL, start 2,000 IU of cholecalciferol (D3) daily with a fat-containing meal. Recheck levels in 10-12 weeks.